8-K: Zenas BioPharma's Obexelimab Phase 3 Success in IgG4-RD

Zenas BioPharma announced positive Phase 3 trial results for obexelimab in IgG4-RD, paving the way for regulatory submissions and extending its cash runway through 2026.

Summary

• Zenas BioPharma reported preliminary unaudited cash, cash equivalents, and investments of approximately $360.5 million as of December 31, 2025, which is expected to fund operating expenses and capital expenditure requirements through the end of 2026.
• Obexelimab met the primary endpoint in the registration-directed Phase 3 INDIGO trial for immunoglobulin G4-related disease (IgG4-RD), demonstrating a highly statistically significant 56% reduction in the risk of IgG4-RD flare compared to placebo (Hazard Ratio 0.443, p=0.0005).
• Obexelimab also met and demonstrated highly statistically significant activity on all four key secondary endpoints, including time to first investigator-determined flare (p=0.0001), number of flares (p=0.0008), proportion of patients achieving complete remission (p=0.0049), and cumulative use of rescue therapy (p=0.0042).
• The safety profile of obexelimab was consistent with previous trials, showing lower incidences of serious adverse events (10% vs. 19% placebo) and overall infections (Grade 3 infections: 2% vs. 4% placebo) compared to placebo.
• The company anticipates submitting a Biologics License Application (BLA) to the U.S. FDA for obexelimab in IgG4-RD in the second quarter of 2026 and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in the second half of 2026.
• Zenas is not currently eligible for a $75 million milestone payment from Royalty Pharma Investments 2019 ICAV (RPI) related to the INDIGO Data Milestone, but active discussions are ongoing.
• Upcoming milestones include reporting obexelimab Phase 2 MoonStone trial results in Relapsing Multiple Sclerosis in Q1 2026 and topline results from the Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) in Q4 2026.
• A global Phase 3 trial of orelabrutinib in non-active Secondary Progressive Multiple Sclerosis (naSPMS) is expected to be initiated in Q1 2026, and Phase 1 clinical development for ZB021 and ZB022 is expected to begin in 2026, pending IND clearance.

Sentiment

Score: 9

Explanation: The filing reports highly positive Phase 3 clinical trial results for obexelimab in IgG4-RD, meeting all primary and key secondary endpoints with a favorable safety profile. This significantly de-risks the lead candidate and paves the way for regulatory submissions. The company also has a strong cash runway and a robust pipeline with multiple upcoming milestones, despite a minor issue with one milestone payment.

Positives

• Obexelimab met its primary endpoint in the Phase 3 INDIGO trial for IgG4-RD, showing a highly statistically significant 56% reduction in flare risk (Hazard Ratio 0.443, p=0.0005).
• All four key secondary efficacy endpoints were also met with high statistical significance, reinforcing the drug's broad effectiveness.
• Obexelimab demonstrated a favorable safety profile, with lower incidences of serious adverse events (10% vs. 19% placebo) and infections (Grade 3 infections: 2% vs. 4% placebo) compared to placebo.
• The company has a preliminary unaudited cash, cash equivalents, and investments balance of approximately $360.5 million as of December 31, 2025, providing a runway through the end of 2026.
• Plans are in place for BLA submission to the FDA in Q2 2026 and MAA submission to the EMA in H2 2026, indicating rapid progression towards commercialization.
• Obexelimab's unique mechanism of B cell inhibition (rather than depletion) and at-home subcutaneous self-administration offer potential advantages over existing treatments for autoimmune diseases.
• The positive INDIGO trial results build upon previously reported highly positive Phase 2 MoonStone trial results in Relapsing Multiple Sclerosis, further validating obexelimab's mechanism of action.

Negatives

• The company is not currently eligible for a $75 million milestone payment from Royalty Pharma Investments 2019 ICAV (RPI) related to the INDIGO Data Milestone, although active discussions are ongoing.
• The reported cash, cash equivalents, and investments amount is preliminary and unaudited, subject to completion of financial closing procedures, and may differ materially from the final audited amount.

Risks

• Limited operating history and anticipation of incurring substantial and increasing losses for the foreseeable future.
• Need for substantial additional financing to achieve company goals.
• Uncertainty, length, and expense of clinical development, with risks of additional costs or delays in completing, or failing to complete, development and commercialization of product candidates.
• Delays or difficulties in the enrollment and dosing of patients in clinical trials.
• Impact of any significant adverse events or undesirable side effects caused by product candidates.
• Potential competition from large and specialty pharmaceutical and biotechnology companies with approved therapies in current indications.
• Ability to realize the benefits of current or future collaborations or licensing arrangements and successfully consummate future partnerships.
• Ability to obtain regulatory approval to commercialize any product candidate, and the risk that data may not satisfy regulatory authorities or approval may be for a more narrow indication.
• Dependence on the services of senior management and other clinical and scientific personnel, and the ability to retain or recruit these individuals.
• Ability to grow the organization and manage the growth and expansion of operations.
• Risks related to the complex manufacturing of product candidates and potential difficulties with third-party manufacturers.
• Ability to obtain and maintain sufficient intellectual property protection for product candidates.
• Reliance on third parties to conduct preclinical studies and clinical trials.
• Compliance with obligations under licenses granted by others for development and commercialization rights.
• Significant political, trade, and regulatory developments, including changes in relations between the U.S. and China.
• Risks related to the operations of suppliers located outside of the United States, including WuXi Biologics (Hong Kong) Limited and InnoCare, both located in China.
• Forward-looking statements are inherently uncertain, speak only as of the date of the report, and may prove incorrect.

Future Outlook

Zenas BioPharma anticipates submitting a BLA to the FDA for obexelimab in IgG4-RD in Q2 2026 and an MAA to the EMA in H2 2026. The company expects to report obexelimab Phase 2 MoonStone trial results in Relapsing Multiple Sclerosis in Q1 2026 and topline results from the Phase 2 SunStone trial in SLE in Q4 2026. A global Phase 3 trial for orelabrutinib in naSPMS is expected to initiate in Q1 2026. Additionally, Phase 1 clinical development for ZB021 and ZB022 is expected to begin in 2026, pending IND clearance, with plans to advance development for rheumatic/dermatologic and neurologic diseases, respectively.

Management Comments

• "Given obexelimab's significant clinical activity and the compelling safety and tolerability profile observed in the INDIGO trial, we believe obexelimab may have an important role as a first line therapy in the long-term management of IgG4-RD." Lonnie Moulder, Founder and Chief Executive Officer of Zenas.
• "With its unique inhibitory mechanism, tolerability profile, at-home subcutaneous self-administration and potential to pause for vaccination or management of intercurrent illness, obexelimab has the potential to be a meaningful treatment option for patients." Lonnie Moulder, Founder and Chief Executive Officer of Zenas.
• "IgG4-RD represents a significant commercial opportunity for obexelimab and Zenas, and today's data support obexelimab as a potential franchise molecule for rheumatic diseases." Lonnie Moulder, Founder and Chief Executive Officer of Zenas.
• "The INDIGO study results suggest that obexelimab, with its intriguing mechanism of action — emphasizing B cell inhibition rather than B cell depletion — and self-administration by patients, may be an important new therapy for people living with IgG4-RD." John Stone, M.D., M.P.H., Professor of Medicine at Harvard Medical School.
• "These INDIGO trial results build upon the highly positive results observed in our Phase 2 MoonStone trial in Relapsing Multiple Sclerosis and further validate obexelimab's mechanism of action, optimized subcutaneous dosing and its potential to address the unmet medical needs of patients living with autoimmune diseases." Lisa von Moltke, M.D., Head of Research and Development and Chief Medical Officer of Zenas.
• "Obexelimab's unique inhibitory mechanism, combined with its weekly subcutaneous dosing chosen for optimal pharmacokinetic and clinical activity, has the potential to sustain B cell inhibition and durably impact disease activity." Lisa von Moltke, M.D., Head of Research and Development and Chief Medical Officer of Zenas.

Industry Context

Immunoglobulin G4-Related Disease (IgG4-RD) is a chronic fibro-inflammatory condition with limited treatment options, often leading to severe organ damage. Current therapies, such as glucocorticoids (GCs) and B cell depleting agents (e.g., rituximab), carry significant drawbacks including long-term complications, high relapse rates, and compromised immune responses. Obexelimab's mechanism of B cell *inhibition* rather than *depletion*, coupled with its favorable safety profile and convenient self-administration, positions it as a potentially differentiated and safer first-line therapy. This addresses a significant unmet medical need in a market estimated at approximately 20,000 diagnosed patients in the U.S., representing a substantial commercial opportunity for Zenas BioPharma.

Comparison to Industry Standards

• Existing B cell depleting agents (e.g., rituximab) for IgG4-RD can compromise vaccination response and increase infection risk; obexelimab's B cell *inhibition* mechanism aims to mitigate these issues by not depleting B cells.
• Glucocorticoids (GCs), commonly used off-label, are associated with long-term complications, high relapse rates (most patients relapse within 12 months), and do not address underlying disease activity; obexelimab offers a potential long-term management option with a different therapeutic approach.
• Obexelimab's safety profile, with lower serious adverse events (10% vs. 19% placebo) and infections (Grade 3: 2% vs. 4% placebo), appears favorable compared to the known side effects and risks associated with long-term GC use and B cell depleting agents.
• The INDIGO trial, enrolling 194 patients, represents the largest body of clinical data ever reported in the IgG4-RD indication, providing robust evidence for obexelimab's efficacy and safety, setting a new benchmark for clinical evidence in this rare disease.

Stakeholder Impact

• Shareholders: Positive impact due to successful Phase 3 trial, de-risking of lead asset, potential for regulatory approval and commercialization, and extended cash runway. Potential for future milestone payments.
• Patients (IgG4-RD): Significant positive impact with a potential new, effective, and well-tolerated treatment option that addresses unmet medical needs and offers a different mechanism of action compared to existing therapies.
• Employees: Positive impact from successful clinical development, potentially leading to increased commercialization efforts and company growth.
• Regulatory Authorities (FDA, EMA): Will receive BLA/MAA submissions for review.
• Bristol Myers Squibb Company: As a partner holding exclusive development and commercialization rights in certain Asian and Australian territories, they benefit from the positive trial results.
• Royalty Pharma Investments 2019 ICAV (RPI): Their investment in obexelimab revenue streams is validated by the positive trial results, although the immediate INDIGO Data Milestone payment is under discussion.

Next Steps

• Submit Biologics License Application (BLA) to the U.S. FDA for obexelimab in IgG4-RD in Q2 2026.
• Submit Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for obexelimab in IgG4-RD in H2 2026.
• Report obexelimab 24-week Phase 2 MoonStone trial results in Relapsing Multiple Sclerosis in Q1 2026.
• Initiate global Phase 3 trial of orelabrutinib in non-active Secondary Progressive Multiple Sclerosis (naSPMS) in Q1 2026.
• Report topline results, including biomarker analysis, of obexelimab Phase 2 SunStone trial in SLE in Q4 2026.
• Initiate Phase 1 clinical development for ZB021 (oral IL-17AA/AF inhibitor) in 2026, pending IND clearance.
• Initiate Phase 1 clinical development for ZB022 (brain penetrant TYK2 inhibitor) in 2026, pending IND clearance.
• Advance development of ZB021 for rheumatic and/or dermatologic diseases, pending Phase 1 data.
• Advance development of ZB022 for neurologic diseases, pending Phase 1 data.
• Present full data from the INDIGO trial at a future medical meeting.
• Continue active discussions with RPI regarding the INDIGO Data Milestone payment.

Key Dates

Recommendation

The successful Phase 3 INDIGO trial for obexelimab in IgG4-RD is a major de-risking event for Zenas BioPharma's lead asset, demonstrating highly statistically significant efficacy and a favorable safety profile. This paves a clear path for regulatory submissions in the US and Europe, indicating strong commercial potential in an area with unmet medical needs. The company also boasts a robust cash runway through the end of 2026 and a promising pipeline with multiple upcoming catalysts, including further trial results and new program initiations. While a $75 million milestone payment is currently under discussion, the overall positive clinical outcome and strategic positioning far outweigh this minor uncertainty. This news significantly enhances the company's valuation and future prospects, making it a compelling investment opportunity.

Keywords

Zenas BioPharma, ZBIO, obexelimab, IgG4-RD, Immunoglobulin G4-Related Disease, Phase 3, INDIGO trial, Biologics License Application, BLA, FDA, Marketing Authorization Application, MAA, EMA, autoimmune diseases, B cell inhibition, orelabrutinib, Multiple Sclerosis, Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Systemic Lupus Erythematosus, SLE, BTK inhibitor, ZB021, IL-17AA/AF inhibitor, ZB022, TYK2 inhibitor, clinical trial, biopharmaceutical, drug development, regulatory submission, cash runway, financial results